Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung

被引:1
作者
Duygulu, Mustafa Emre [1 ]
Asik, Esra [1 ]
Tukenmez, Mehmet Akif [1 ]
Teoman, Gizem [2 ]
Yildirim, Atila [3 ]
Fidan, Evren [1 ]
机构
[1] Karadeniz Tech Univ, Farabi Hosp, Dept Med Oncol, Trabzon, Turkiye
[2] Karadeniz Tech Univ, Farabi Hosp, Dept Med Pathol, Trabzon, Turkiye
[3] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkiye
来源
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA | 2024年 / 70卷 / 09期
关键词
Neuroendocrine carcinoma; Lung cancer; Ki-67;
D O I
10.1590/1806-9282.20240398
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Large cell neuroendocrine carcinoma of the lung is a rare type of lung cancer. There is a limited number of studies on clinical and histopathological characteristics that are effective in survival. The aim of this study was to investigate the relationship between histopathological and clinical characteristics, mainly Ki-67 proliferation index, and survival in patients diagnosed with large cell neuroendocrine carcinoma of the lung. METHODS: The data of 38 patients followed up with the diagnosis of large cell neuroendocrine carcinoma of the lung were evaluated. The mean Ki-67 value was determined to be 65.8% (+/- 20.8). The patients' clinical characteristics and survival times were compared according to the cut-off value determined for Ki-67 index. RESULTS: When median overall survival times were compared, it was seen that overall survival was numerically lower in patients aged 65 years and over, in tumors located on the right side, in cases who were in the metastatic stage at diagnosis, whose Ki-67 index was 65% and above, who did not receive chemotherapy, who did not undergo curative surgery, and in patients with chronic diseases (p>0.05). In the Kaplan-Meier analysis, the median overall survival was determined to be 22.2 months (95%CI 21.7-22.7) in the patients with Ki-67<65%, while it was found to be 20.3 months (95%CI 4.5-36.2) in the patients with Ki-67 >= 65% (p=0.351). CONCLUSION: Our study identified subgroups with decreased survival in large cell neuroendocrine carcinoma of lung patients. Studies including a larger number of patients are needed to identify the prognostic importance of these clinical and histopathological characteristics.
引用
收藏
页数:6
相关论文
共 15 条
[1]   Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer [J].
Davey, Matthew G. ;
Hynes, Sean O. ;
Kerin, Michael J. ;
Miller, Nicola ;
Lowery, Aoife J. .
CANCERS, 2021, 13 (17)
[2]   Pulmonary Large-Cell Neuroendocrine Carcinoma From Epidemiology to Therapy [J].
Fasano, Morena ;
Della Corte, Carminia Maria ;
Papaccio, Federica ;
Ciardiello, Fortunato ;
Morgillo, Floriana .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) :1133-1141
[3]   Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer [J].
Fernandez, Felix G. ;
Battafarano, Richard J. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2006, 18 (03) :206-210
[4]   The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung [J].
Gazdar, Adi F. ;
Savage, Trisha K. ;
Johnson, Jane E. ;
Berns, Anton ;
Sage, Julien ;
Linnoila, R. Ilona ;
MacPherson, David ;
McFadden, David G. ;
Farago, Anna ;
Jacks, Tyler ;
Travis, William D. ;
Brambilla, Elisabeth .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) :553-564
[5]   Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer [J].
Ishibashi, Naoya ;
Maebayashi, Toshiya ;
Aizawa, Takuya ;
Sakaguchi, Masakuni ;
Nishimaki, Haruna ;
Masuda, Shinobu .
RADIATION ONCOLOGY, 2017, 12
[6]   High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma A Comprehensive Meta-Analysis with 13,053 Patients Involved [J].
Luo, Yihuan ;
Zhang, Xin ;
Mo, Meile ;
Tan, Zhong ;
Huang, Lanshan ;
Zhou, Hong ;
Wang, Chunqin ;
Wei, Fanglin ;
Qiu, Xiaohui ;
He, Rongquan ;
Chen, Gang .
MEDICINE, 2016, 95 (15)
[7]   Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis [J].
Milione, Massimo ;
Maisonneuve, Patrick ;
Grillo, Federica ;
Mangogna, Alessandro ;
Centonze, Giovanni ;
Prinzi, Natalie ;
Pusceddu, Sara ;
Garzone, Giovanna ;
Cattaneo, Laura ;
Busico, Adele ;
Bossi, Paola ;
Spaggiari, Paola ;
Pellegrinelli, Alessio ;
Del Gobbo, Alessandro ;
Ferrero, Stefano ;
Kankava, Ketevani ;
Pruneri, Giancarlo ;
Rolli, Luigi ;
Roca, Elisa ;
Bercich, Luisa ;
Tironi, Andrea ;
Benvenuti, Mauro Roberto ;
Gallazzi, Maria Sole ;
Romano, Rosalia ;
Berruti, Alfredo ;
Pastorino, Ugo ;
Capella, Carlo .
NEUROENDOCRINOLOGY, 2021, 111 (05) :475-489
[8]   The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 [J].
Nicholson, Andrew G. ;
Tsao, Ming S. ;
Beasley, Mary Beth ;
Borczuk, Alain C. ;
Brambilla, Elisabeth ;
Cooper, Wendy A. ;
Dacic, Sanja ;
Jain, Deepali ;
Kerr, Keith M. ;
Lantuejoul, Sylvie ;
Noguchi, Masayuki ;
Papotti, Mauro ;
Rekhtman, Natasha ;
Scagliotti, Giorgio ;
van Schil, Paul ;
Sholl, Lynette ;
Yatabe, Yasushi ;
Yoshida, Akihiko ;
Travis, William D. .
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) :362-387
[9]   The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5 [J].
Popa, Oana ;
Taban, Sorina Maria ;
Pantea, Stelian ;
Plopeanu, Andrei Dorel ;
Barna, Robert Alexandru ;
Cornianu, Marioara ;
Pascu, Anca-Ariana ;
Dema, Alis Liliana Carmen .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (04)
[10]   Lung neuroendocrine neoplasms: recent progress and persistent challenges [J].
Rekhtman, Natasha .
MODERN PATHOLOGY, 2022, 35 (SUPPL 1) :36-50